Repression of VEGFA by CA-rich element-binding microRNAs is modulated by hnRNP L

Faegheh Jafarifar1,2, Peng Yao1, Sandeepa M Eswarappa1 and Paul L Fox1,2,*

1Department of Cell Biology, The Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA and 2Department of Biochemistry, Case Western Reserve University, School of Medicine, Cleveland, OH, USA

Expression of vascular endothelial growth factor-A (VEGFA) by tumour-associated macrophages is critical for tumour progression and metastasis. Hypoxia, a common feature of the neoplastic microenvironment, induces VEGFA expression by increased transcription, translation, and mRNA stabilization. Here, we report a new mechanism of VEGFA regulation by hypoxia that involves reversal of microRNA (miRNA)-mediated silencing of VEGFA expression. We show that the CA-rich element (CARE) in the human VEGFA 3′-UTR is targeted by at least four miRNAs. Among these miRNAs, miR-297 and -299 are endogenously expressed in monocytic cells and negatively regulate VEGFA expression. Unexpectedly, hypoxia completely reverses miRNA-mediated repression of VEGFA expression. We show that heterogeneous nuclear ribonucleoprotein L (hnRNP L), which also binds the VEGFA 3′-UTR CARE, prevents miRNA silencing activity. Hypoxia induces translocation of nuclear hnRNP L to the cytoplasm, which markedly increases hnRNP L binding to VEGFA mRNA thereby inhibiting miRNA activity. In summary, we describe a novel regulatory mechanism in which the interplay between miRNAs and RNA-binding proteins influences expression of a critical hypoxia-inducible angiogenic protein. These studies may contribute to provide miRNA-based anticancer therapeutic tools.

The EMBO Journal (2011) 30, 1324–1334. doi:10.1038/emboj.2011.38; Published online 22 February 2011

Subject Categories: RNA

Keywords: CA-rich element; heterogeneous nuclear ribonucleoprotein L; hypoxia; microRNA; vascular endothelial growth factor-A

Introduction

The recruitment and infiltration of tumour-associated macrophages (TAMs) is a prominent feature of most solid tumours, and they have a principal role in tumour progression and metastasis (Lin et al., 2006; Stockmann et al., 2008). TAMs display a relatively immature phenotype but are conditioned by the hypoxic tumour microenvironment to upregulate tumourigenic genes, including vascular endothelial growth factor-A (VEGFA), a critical regulator of angiogenesis (Ferrara, 2005). TAM-derived VEGFA is primarily responsible for the ‘angiogenic switch’ that initiates tumour vascularization, and it cannot be compensated by VEGFA from other cell sources within the tumour (Lin et al., 2006; Qian and Pollard, 2010).

Hypoxia induces VEGFA expression by increased transcription, translation, and mRNA stabilization. Post-transcriptional induction of VEGFA by hypoxia is mediated by specific mRNA-binding proteins (Claffey et al., 1998; Levy, 1998; Shih and Claffey, 1999; Vumbaca et al., 2008; Ray et al., 2009). The proximal human VEGFA 3′-UTR contains a 126-nt AU-rich domain, termed the hypoxia stability region (HSR), that is critical for VEGFA mRNA stabilization under hypoxia (Claffey et al., 1998). The cytoplasmic interaction of heterogeneous nuclear ribonucleoprotein L (hnRNP L), a splicing factor with extranuclear activities (Piniol-Roma et al., 1989), with the HSR is required for VEGFA mRNA stabilization during hypoxia (Shih and Claffey, 1999). Two adjacent cis-elements have been identified in the VEGFA HSR: a 21-nt CA-rich element (CARE) that binds with high affinity to hnRNP L (Shih and Claffey, 1999) and a 29-nt GAIT (interferon-γ-activated inhibitor of translation) element that binds the heterotetrameric GAIT complex and silences inflammatory gene expression (Ray and Fox, 2007). In hypoxia, a conformational switch in the VEGFA HSR, dictated by mutually exclusive binding of the GAIT complex and hnRNP L, overrides the repressive effect of the GAIT complex and permits high-level VEGFA translation (Ray et al., 2009).

miRNAs (miRNAs) are endogenous, ~21-nt RNA regulators of gene expression (Farh et al., 2005; Rana, 2007; Filipowicz et al., 2008; Bartel, 2009). About 30% of human genes are under the control of one or more miRNAs (Chen and Rajewsky, 2006). They are constituents of miRNA-RNA-induced silencing complexes (miRISCs), and guide these complexes to specific mRNA targets bearing miRNA-binding sites (Rana, 2007; Bartel, 2009). In metazoans, miRISCs silence gene expression by translational repression, mRNA degradation, or a combination of both (Nilsen, 2007; Filipowicz et al., 2008; Eulalio et al., 2008a). Most studies suggest that miRNAs do not switch off their target genes completely, but rather fine-tune expression (Hobert, 2007; Karres et al., 2007; Baek et al., 2008; Bartel, 2009). miRNA expression and activity are tissue-, cell-, and developmental stage-specific (Lagos-Quintana et al., 2002; Lim et al., 2005), and aberrant function can contribute to disease (Kloosterman and Plasterk, 2006; Voorhoeve et al., 2006). VEGFA mRNA is targeted and silenced by miR-15, -16, -20a, and -20b and their downregulation by hypoxia contributes to increased VEGFA expression (Hua et al., 2006; Karaa et al., 2009; Lei et al., 2009).

An additional layer of regulatory complexity is introduced by the superimposition of crosstalk between miRNAs and RNA-binding proteins (RBPs). RBP interaction with the 3′-UTR of miRNAs can modulate activity of miRNAs, either
reducing (Bhattacharyya et al., 2006; Mishima et al., 2006; Huang et al., 2007; Kedde et al., 2007) or enhancing (Hammell et al., 2009; Schwamborn et al., 2009) miRNA activity. Alternatively, RBP function can be modulated by miRNA (Eiring et al., 2010). Because RBPs and miRNAs that bind mRNA 3'-UTRs are diverse and abundant, we anticipate that many examples of these types of complex regulatory interactions are yet to be discovered (Filipowicz et al., 2008). In this report, we reveal a novel mechanism of VEGFA gene regulation involving condition-dependent crosstalk of miRNAs and an RBP. Specifically, we show that miR-297 and -299 are endogenous negative regulators of VEGFA expression in human monocytic cells, and that their function is negatively modulated by hnRNP L during hypoxia.

Results

miRNAs target the 3'-UTR CARE of VEGFA mRNA and inhibit its translation

The 21-nt CARE in the HSR of the VEGFA 3'-UTR is critical for post-transcriptional regulation of VEGFA during hypoxia.

Figure 1 CARE in human VEGFA 3'-UTR is targeted by miRNAs. (A) Schematic of human VEGFA 3'-UTR elements. The full-length VEGFA 3'-UTR (top) is expanded to show elements in the HSR (middle) and the sequence of the CARE and seed regions of predicted CARE-binding miRNAs (bottom). (B) CARE-binding miRNA candidates. (C) CARE-binding miRNAs inhibit expression of reporter bearing human VEGFA HSR. Fluc reporter constructs in pCDNA3 vector bearing either wild type (left) or mutant (right) CARE in the HSR were transfected into HEK293T cells with CARE-binding miRNA candidates (miR-297, -299, -567, and -609), miR-control (Cont.), negative controls (miR-410 and -369), and with RLuc-expressing pRL-SV40 vector as internal control. Relative Luc levels were measured after 24 h and expressed as percentage of control. Results are expressed as mean ± s.d., for n = 3 independent experiments. An asterisk (*) indicates a significant difference, P<0.05, two-tailed t-test.
To investigate the effect of CARE-targeting miRNAs on endogenous VEGFA expression in myeloid cells, the miRNAs were overexpressed by transient transfection of U937 monocytic cells, and VEGFA was determined in cell lysates by immunoblot analysis. VEGFA expression was reduced by miR-297, -299, -567, and -609 by about 50–70% compared with controls (Figure 2A). As before, GAIT-element-targeting miRNAs were ineffective. In a positive control experiment, miR-16, which binds the distal 3′-UTR (nt 1793–1818) of human VEGFA and downregulates its expression (Karaa et al, 2009), markedly repressed VEGFA expression.

miRNAs can silence gene expression by mRNA degradation or translation inhibition (Bartel, 2004; Guo et al, 2010). Quantitative real-time RT–PCR showed that CARE-binding miRNAs did not alter VEGFA mRNA expression, suggesting inhibition at the level of translation (Figure 2B). To confirm the silencing mechanism, translation efficiency was determined by polysome fractionation. A firefly luciferase (FLuc) reporter mRNA upstream of the VEGFA HSR was cotransfected with miR-299 into HEK293T cells. After 24 h, cell lysates were fractionated by sucrose gradient fractionation and RNA was monitored by absorption at 254 nm (Figure 2C, top panels). RT–PCR analysis using FLuc-specific primers showed that miR-299 shifted the reporter from the rapidly translating to the non-translating fractions (Figure 2C, middle panels). As a control, GAPDH mRNA was primarily detected in the translating fractions and was unaffected by miR-299 (Figure 2C, bottom panels). Together, these results indicate translational inhibition as the mechanism by which CARE-binding miRNA reduces VEGFA expression.

**Role of endogenous CARE-binding miRNAs in regulating VEGFA expression**

The endogenous levels of miR-297, -299, -567, and -609 were measured in monocytic cells by RNA blot using miRNA-specific probes. miR-297 and -299 were detected at comparable levels in human U937 and THP1 cell lines, and in human peripheral blood monocytes (PBMs) (Figure 3A); miR-567 and -609 were not detected in any of the cells (not shown).

To determine the effect of endogenous miRNAs on VEGFA expression, U937 cells were cotransfected with FLuc reporter bearing the VEGFA HSR and either control miRNA (left) or miR-299 (right). Lysates were subjected to sucrose density gradient fractionation and RNA was monitored by absorption at 254 nm. RNA isolated from each fraction was subjected to RT–PCR to determine FLuc and GAPDH (middle and right). Lysates were subjected to sucrose density gradient fractionation and RNA was monitored by absorption at 254 nm (top). RNA isolated from each fraction was subjected to RT–PCR to determine FLuc (middle) and GAPDH (right). Lysates were subjected to sucrose density gradient fractionation and RNA was monitored by absorption at 254 nm (top). RNA isolated from each fraction was subjected to RT–PCR to determine FLuc (middle) and GAPDH (bottom). Results are expressed as mean ± s.d., for n = 3 independent experiments. An asterisk indicates a significant difference, P<0.05, two-tailed t-test.

**Figure 2** The effect of CARE-binding miRNAs on VEGFA expression. (A) Ectopically expressed CARE-binding miRNAs inhibit VEGFA expression. U937 cells were transfected with CARE-binding miRNAs or controls. After 24 h, cell lysates were subjected to immunoblot analysis with anti-VEGFA (top) or anti-GAPDH (middle) antibodies. VEGFA expression was quantitated and expressed as percentage of control (B) CARE-binding miRNAs do not inhibit VEGFA mRNA expression. After transfection with miRNAs for 24 h, VEGFA mRNA amount was measured by real-time, quantitative RT–PCR and normalized to GAPDH mRNA. (C) CARE-binding miRNAs repress translation of HSR-bearing reporter RNA. HEK293T cells were cotransfected for 24 h with FLuc reporter bearing the VEGFA HSR and either control miRNA (left) or miR-299 (right). Lysates were subjected to sucrose density gradient fractionation and RNA was monitored by absorption at 254 nm (top). RNA isolated from each fraction was subjected to RT–PCR to determine FLuc (middle) and GAPDH (bottom) mRNAs. Results are expressed as mean ± s.d., for n = 3 independent experiments. An asterisk indicates a significant difference, P<0.05, two-tailed t-test.
secretory protein and transfection with either anti-miR-297 or -299 induced nearly a two-fold increase in 24 h conditioned medium (Figure 3D). These results indicate a physiological role of endogenous miR-297 and -299 in negative regulation of VEGFA in monocytic cells.

**Hypoxia prevents activity of miRNAs targeting the VEGFA CARE**

miRNA activity can be modulated in a state-specific manner, for example, by cell stress (Bhattacharyya et al, 2006; Huang et al, 2007; Kedde et al, 2007; Hammell et al, 2009), thus we investigated whether hypoxia, an established regulator of VEGFA expression, modulates the activity of CARE-binding miRNAs. The repressive activity of CARE-binding miRNAs was almost completely alleviated by hypoxia (Figure 4A). The effect of hypoxia was specific for miRNAs targeting the CARE as repression by miRNAs targeting other regions of the VEGFA 3’-UTR (Hua et al, 2006; Karara et al, 2009; Lei et al, 2009), for example, miR-16 (Figure 4A) or miR-20a and miR-20b (data not shown) was observed in both conditions. We considered the possibility that hypoxia decreased the amount of CARE-targeting miRNAs, thereby reducing its effect on VEGFA expression. RNA blot analysis showed that hypoxia did not alter endogenous expression of CARE-binding miR-297 or -299 (Figure 4B). This result was confirmed by quantitative RT–PCR in both U937 cells and PBM (Figure 4C). These findings suggest that hypoxia might influence non-miRNA, trans-acting factors that target the VEGFA mRNA CARE.

**Hypoxia induces hnRNPL translocation and binding to VEGFA mRNA**

hnRNPL is an abundant nucleocytoplasmic protein that binds the VEGFA CARE in human melanoma cells and increases VEGFA mRNA stability during hypoxia (Shih and Claffey, 1999). Quantitative RT–PCR (Figure 5A, top) and RNA blot analysis (not shown) showed that exposure of U937 cells to hypoxia did not significantly alter hnRNPL expression. Likewise, immunoblot analysis of cell lysates showed no effect of hypoxia on hnRNPL protein expression (Figure 5A, bottom two panels). We investigated the effect of hypoxia on hnRNPL localization. Immunofluorescence detection indicated that hnRNPL is primarily localized in the nucleus of U937 cells under normoxic conditions, but after 24 h treatment with hypoxia, substantial hnRNPL is observed in the cytoplasm (Figure 5B). To confirm the subcellular localization of hnRNPL, cell fractionation studies were done in U937 cells and PBM exposed to hypoxia or normoxia for 24 h and nuclear and cytoplasmic lysates were prepared. Hypoxia increased the cytoplasmic level of hnRNPL L by three- to five-fold in both cell types (Figure 5C).

We investigated whether hypoxia induces an interaction between hnRNPL and VEGFA mRNA in monocytic cells. Following a 24-h treatment of U937 cells with hypoxia or normoxia, cytosolic lysates were subjected to immunoprecipitation with monoclonal anti-hnRNPL antibody, immunoprecipitated with polyclonal anti-VEGFA antibody, immu

---

**Figure 3** Presence and activity of endogenous CARE-binding miRNAs. (A) miR-297 and -299 are endogenously expressed in monocytic cells. Total small RNAs were isolated from human U937 cells, THP1 cells, and PBM under normoxic condition. RNA was subjected to RNA blot analysis using probes against miR-297 (top), miR-299 (middle), and U6 as control (bottom). (B) Endogenous miR-297 and -299 negatively regulate expression of HSR-bearing reporter. FLuc reporter upstream of the HSR was cotransfected with anti-miR-297, -299, random sequence control (Cont.), or mutated anti-miR-297 or -299, and with RLuc-expressing vector pRL-SV40 as control for transfection efficiency. After 24 h, the relative Luc levels were determined, and expressed as fold-change compared with random control. (C) Endogenous miR-297 and -299 negatively regulate endogenous VEGFA expression. U937 cells were transfected with anti-miR-297, -299, or controls as above. Cell lysates subjected to immunoblot analysis with anti-VEGFA (top) and -GAPDH (middle) antibodies. The amount of VEGFA was expressed as percentage of random control (bottom). (D) miR-297 and -299 negatively regulate VEGFA secretion. Cells were transfected as in (C) and conditioned medium concentrated by immunoprecipitation with polyclonal anti-VEGFA antibody,immunoprecipitated with monoclonal anti-VEGFA antibody (top) and quantitated by densitometry (bottom). Results are expressed as mean ± s.d., for n = 3 independent experiments. An asterisk indicates a significant difference, P < 0.05, two-tailed t-test.
hnRNP L and VEGFA mRNA occurs in the nucleus, followed by transport to the cytoplasm, as would be expected for a shuttling factor. Both precursor and mature VEGFA mRNAs are detected in the nuclear lysates from cells treated with normoxia or hypoxia (Figure 5E, top). The same lysates were subjected to immunoprecipitation with anti-hnRNP L antibody and RT–PCR for VEGFA mRNA and pre-mRNA. hnRNP L binding to VEGFA pre-mRNA in the nucleus was detected, but binding to the mature mRNA was not (Figure 5E, middle). Immunoprecipitation using anti-hnRNP A1 was used as a positive control since it interacts with pre-mRNAs and remains mRNA-bound during transport to the cytoplasm (Mili et al., 2001). As expected, hnRNP A1 bound both VEGFA mRNA forms in the nucleus. RT–PCR with primers specific for GAPDH mRNA verified the selectivity of the interaction between VEGFA mRNA and hnRNP L (Figure 5E, bottom). We conclude that the interaction between hnRNP L and mature VEGFA mRNA occurs in the cytoplasm and is independent of nucleocytoplasmic transport.

Role of hnRNP L in overcoming miRNA-mediated repression of VEGFA

To determine whether the increase in cytoplasmic hnRNP L in hypoxia is sufficient to induce binding to VEGFA mRNA, we overexpressed hnRNP L and determined its binding to VEGFA mRNA in normoxia. U937 cells were transfected with pcDNA3-c-Myc-hnRNP L (or empty vector) for 24 h under normoxic condition and expression confirmed by immunoblot using anti-c-Myc antibody (Figure 6A, top two panels). Immunoprecipitation of cell lysate with anti-hnRNP L antibody, followed by RT–PCR with VEGFA or GAPDH-specific primers revealed a selective interaction (Figure 6A, bottom two panels). Interestingly, the finding that ectopically expressed hnRNP L binds VEGFA mRNA suggests hypoxia or other hypoxia-inducible factors are not required, but rather the cytoplasmic concentration of hnRNP L determines its association with VEGFA mRNA. To specifically show the role of hnRNP L in overcoming miRNA-mediated inhibition, HEK293T cells were cotransfected with an expression vector

Figure 4 Hypoxia inhibits the activity of CARE-binding miRNAs. (A) Hypoxia overcomes miRNA-mediated inhibition of VEGFA expression. U937 cells were incubated with miRNAs under normoxic (21% pO2, N) or hypoxic (1% pO2, H) conditions for 24 h. Cell lysates were subjected to immunoblot analysis with anti-VEGFA (top) and anti-GAPDH (middle) antibodies; VEGFA was expressed as percentage of normoxic control (bottom). (B) Hypoxia does not inhibit expression of miR-297 and -299. U937 cells were incubated under conditions of normoxia (Nmx.) or hypoxia (Hpx.) for 24 h and miR-297 and -299 determined by RNA blot analysis using LNA oligomer probes and U6 probe as loading control. (C) miRNA amounts of normoxia- and hypoxia-treated U937 cells (left) or PBM (right) were determined by real-time quantitative RT–PCR after isolation of total small RNAs. RT–PCR of miR-17-5p was used for normalization. Results are expressed as mean ± s.d., for n = 3 independent experiments. An asterisk indicates a significant difference, P < 0.05, two-tailed t-test.
encoding c-Myc-hnRNP L and FLuc reporter bearing the VEGFA HSR, in addition to CARE-binding miRNAs. Ectopic expression of hnRNP L almost completely restored expression of the reporter in the presence of the inhibitory miRNAs (Figure 6B). Similarly, the effect of hnRNP L on mRNA-mediated regulation of endogenous VEGFA expression was examined. Cotransfection of c-myc-hnRNP L with CARE-binding miRNAs blocked the repressive activity of miRNAs, completely restoring endogenous expression of VEGFA, and verifying the direct role of hnRNP L in preventing the miRNA-mediated inhibition of VEGFA expression (Figure 6C).

**Discussion**

Induction of VEGFA during hypoxia is a critical pathophysiological response facilitated by diverse transcriptional and post-transcriptional mechanisms. The unusually long 3′-UTR of human VEGFA mRNA appears to be a ‘hot-spot’ for post-transcriptional control by hypoxia. Hypoxia stabilizes VEGFA mRNA by interaction of the RBP Hur to AU-rich elements in the 3′-UTR (Brennan and Steitz, 2001; Goldberg-Cohen et al., 2002), or by an independent mechanism in which hnRNP L binds the CARE in the HSR of the 3′-UTR (Claffey et al., 1998; Shih and Claffey, 1999). Hypoxia, via an HSR-mediated mechanism, can increase translation of VEGFA in monocytic cells exposed to interferon-γ. In this case, hypoxia induces a conformational switch in the VEGFA HSR by increasing hnRNP L binding to the CARE, which in turn reduces binding of the GAIT complex to the adjacent GAIT element, and overrides translational repression (Ray et al., 2009). Previous reports have shown that the VEGFA 3′-UTR is targeted by multiple miRNAs. For example, miR-15b, -16, -20a, and -20b downregulate VEGFA expression, but the levels of the miRNAs themselves are downregulated during...
hypoxia, thus enabling VEGFA expression (Hua et al., 2006). Likewise, miR-126 downregulates VEGFA mRNA expression and is postulated to have tumour suppressor function, but its expression is downregulated in lung cancer cells (Liu et al., 2009). Our target analysis (not shown) suggests that the miRNAs in these earlier reports target regions outside of the CARE and HSR of VEGFA.

Our results indicate that at least four miRNAs, miR-297, -299, -567, and -609, target the CARE of human VEGFA 3'-UTR, and when ectopically expressed markedly inhibit VEGFA protein expression. Two of these miRNAs, miR-297 and -299, are endogenously expressed in U937 cells and in freshly isolated human PBM. These miRNAs have no effect on the amount of VEGFA mRNA, indicating that their silencing activity is at the level of mRNA translation. This conclusion was rigorously established for miR-299 that induces a shift of HSR-bearing reporter RNA from the rapidly translating polysome fractions to the non-translating mRNP pool. Although many miRNA-targeted mRNAs undergo extensive degradation (Guo et al., 2010), there are also examples of repression at the translational level, or by a combination of both processes (Eulalio et al., 2008a, b). The molecular determinants and mechanisms that direct RISC-mediated degradation or translational repression have not been elucidated; however, the specific silencing pathway for a given mRNA can be tissue specific or cell specific (Lagos-Quintana et al., 2002).

The inhibitory activity of the miRNAs is prevented during hypoxia by hnRNP L, which translocates from the nucleus to the cytoplasm and binds the CARE in the VEGFA mRNA, presumably blocking the accessibility of the miRISC targeting the same element. Several recent reports have shown that RBPs can modulate repression by miRNAs in a cell state-specific manner (Bhattacharyya et al., 2006; Mishima et al., 2006; Huang et al., 2007; Kedde et al., 2007). For example, HuR binding to the 3'-UTR of CAT-1 mRNA during cellular stress prevents miR-122-mediated repression of CAT-1 expression (Bhattacharyya et al., 2006). Similarly, during germline development in zebrafish, Dnd1 binds U-rich sequences in nanos1 and TDRD7 mRNAs near the binding site of miR-430, relieving its repression (Kedde et al., 2007). In another example of an RBP-disrupting miRNA function, Lin28 selectively blocks the processing of pri-let-7 miRNAs in embryonic cells (Viswanathan et al., 2008). Finally, during synaptic development, brain-derived neurotrophic factor silences mir-134

Figure 6 hnRNP L overexpression increases VEGFA expression in normoxia by inhibiting activity of CARE-binding miRNAs. (A) Overexpressed hnRNP L binds VEGFA mRNA in normoxia. U937 cells were transfected with pcDNA3-c-Myc-hnRNP L or empty vector (Vect.) under normoxia for 24 h. Cytosolic lysates were immunoblotted with anti-c-Myc tag and anti-GAPDH antibodies (top two panels). Cytosolic lysates were subjected to immunoprecipitation with anti-c-Myc tag (top) and -GAPDH antibodies (middle). The relative level of VEGFA was normalized by RT–PCR (bottom two panels). (B) Overexpression of hnRNP L in normoxia prevents miRNA-mediated repression of HSR-bearing reporter. FLuc reporter bearing the HSR was coexpressed with U937 cells with CARE-binding miRNAs (control miRNA, Cont.), pcDNA3-c-Myc-hnRNP L or vector, and RLuc as transfection efficiency control. Lysates were subjected to immunoblot analysis with anti-c-Myc tag (top) and -GAPDH antibodies (middle). The relative level of FLuc was normalized by RLuc expression and expressed as percentage of control (bottom). (C) Overexpressed hnRNP L alleviates miRNA-mediated repression of endogenous VEGFA in normoxia. U937 cells were cotransfected with pcDNA3-c-Myc-hnRNP L or vector and CARE-binding miRNAs for 24 h under normoxia. Lysates were subjected to immunoblot analysis with anti-c-Myc tag, VEGFA, and GAPDH antibodies (the samples were run on the same gel but the lanes were rearranged for clarity). VEGFA expression was quantitated by densitometry and expressed as percent of normoxic control. Results are expressed as mean ± s.d., for n = 3 independent experiments. An asterisk indicates a significant difference, P < 0.05, two-tailed t-test.
Figure 7 Schematic showing effects of CARE-binding miRNAs and hnRNP L on VEGFA expression. In normoxia, translation of VEGFA mRNA is negatively regulated by endogenous miRNA/RISC complexes binding to CARE (left). In hypoxia, hnRNP L is translocated to cytoplasm where it binds CARE, prevents miRNA/RISC activity, and increases VEGFA expression (right).

inhibition of Limk1 mRNA translation by an undefined mechanism (Schratt et al., 2006). In most cases, the RBP inhibits the expression or activity of an miRNA; however, other regulatory interactions between these moieties have been described. For example, several reports have revealed a cooperative interaction between an RBP and a specific miRNA where both are required for repression of gene expression (Hammell et al., 2009; Kim et al., 2009). In another atypical case, miR-328 functions as an mRNA decay by binding to the inhibitory RBP hnRNP E2 and preventing its interaction with target mRNA (Eiring et al., 2010).

The crosstalk between hnRNP L and inhibitory miRNAs described here exhibits several unique characteristics. First, the inhibition of VEGFA expression by endogenous miRNAs occurs under basal conditions in unstimulated cells, and is derepressed upon stress, that is, hypoxia. Second, hypoxia activates hnRNP L by inducing its translocation from the nucleus to the cytoplasm. The molecular mechanism regulating hnRNP L localization is not known; however, another miRNA regulator, HuR, has been shown to undergo stress-dependent translocation to the cytoplasm following dephosphorylation (Kim and Gorospe, 2008). Finally, hnRNP L and miR-297, -299, -567, and -609 share the same target site in the VEGFA 3′-UTR, namely the 20-nt CARE. To our knowledge, this is the first example of a protein-binding regulatory element identified as an mRNA target. The coincidence of the protein and miRNA target site on the VEGFA 3′-UTR, and our finding that hnRNP L binds mature VEGFA mRNA only after transport to the cytoplasm, suggests a specific mechanism. Namely, normoxic monocytic cells constitutively express miR-297 and -299; in the absence of substantial cytoplasmic hnRNP L, these miRNAs bind the 3′-UTR CARE of VEGFA mRNA and repress its expression by inhibiting translation (Figure 7). Upon switching to hypoxia, hnRNP L translocates from the nucleus to cytoplasm where it binds the same CARE region of the VEGFA mRNA, thereby obstructing the miRISC-binding site and preventing the repression of VEGFA expression. Our results suggest that the major function of the endogenous, inhibitory miRNAs is to restrict VEGFA expression during normoxia, and the function of hnRNP L translocation is to overcome this restriction during hypoxia. Unexpectedly, VEGFA expression is not increased in hypoxia in our experiments, and we speculate that additional inhibitory mechanisms might be operative in hypoxic myeloid cells that are balanced by the suppression of miRNA activity by hnRNP L. Together, our results support an intricate interplay of regulatory mechanisms that might function to maintain myeloid cell VEGFA expression at a constant level in both normoxia and hypoxia. miR-297 is also expressed in non-monocytic HEK293T cells, and CARE-binding miRNAs inhibit VEGFA expression in normoxia but not hypoxia, suggesting that the mechanism might be broadly applicable to multiple cell types (Supplementary Figure S1A and B). Interestingly, hypoxia increases VEGFA expression in HEK293T cells compared with normoxic cells, even in the presence of inhibitory miRNAs thus indicating the potential for this mechanism to influence total VEGFA expression in non-myeloid cells.

The discovery of endogenous miRNAs that target and repress VEGFA has physiological and pathophysiological implications. VEGFA is the principal agonist of angiogenesis and is essential for blood vessel formation during development and tissue repair (Ferrara, 2005). VEGFA also induces vessel permeability and leukocyte chemotraction, events associated with chronic inflammation (Ferrara, 2005). Cancer cells ‘hijack’ VEGFA to promote tumour vascularization and growth. Interestingly, recent studies point to the critical importance of VEGFA produced by TAMs for throwing the ‘angiogenic switch’ that induces tumour angiogenesis during hypoxia (Lin et al., 2006; Qian and Pollard, 2010). Overexpression of miR-297, -299, -567, and -609 all cause robust inhibition of VEGFA expression. However, the increase in VEGFA expression observed upon inhibition of endogenous miR-297 and -299 was more modest, consistent with a ‘tuning’ function of the miRNAs rather than an all-or-none response. Recent studies in vertebrates suggest that this type of regulation by miRNAs may be the norm rather than the exception (Hobert, 2007). Experimental criteria for a tuning relationship between an miRNA and its respective target has been suggested: the miRNA and the protein product of the target mRNA must both be present in the cell, and both upregulation and downregulation of the respective target protein must be detrimental (Hobert, 2007). Certainly, the regulation of VEGFA by miR-297 and -299 fulfill these characteristics. Both of the miRNAs as well as VEGFA mRNA and protein are constitutive in monocytic cells. Accumulating evidence suggests that VEGFA expression must be regulated within a relatively narrow range. Deletion of a single VEGFA allele causes abnormal blood vessel formation and mid-gestational lethality in mice (Carmeliet et al., 1996). In contrast, modest overexpression induces aberrant vasculogenesis and heart development, and ultimately, embryonic lethality (Miquerol et al., 2000). In adult humans (and mice), elevated serum VEGFA is associated with a lethal hepatic syndrome (Wong et al., 2001). Interestingly, although reduction of VEGFA level or action by VEGFA or VEGFA receptor antagonists has been successfully applied in cancer therapy, the same repression can cause vascular disturbance, regression of blood vessels, and an array of severe side effects that hamper its clinical applicability (Kamba and McDonald, 2007). Moreover, deletion of macrophage-derived VEGFA results in accelerated tumour growth (Stockmann et al., 2008). These observations strongly indicate that VEGFA must be subject to tight bi-directional regulation. Negative
regulation by miRNAs may contribute to management of VEGFA dosage within the optimal range by providing a negative regulatory effect that partially counterbalances positive transcriptional and post-transcriptional regulatory mechanisms.

Under the conditions of our experiments, hypoxia induces hnRNP L translocation to the cytoplasm where it not only overrides miRNA-mediated inhibition of translation of VEGFA mRNA, but it also stabilizes the transcript (Claffey et al., 1998), both contributing to elevated expression of VEGFA that reverses hypoxia by inducing blood vessel formation. Although we found that hypoxia did not alter miRNA expression, there might be other stress conditions that induce CARE-binding miRNAs to a level that prevents hnRNP L-mediated induction of VEGFA, and in fact, inhibits VEGFA expression. Alternatively, the inhibitory activity of CARE-binding miRNAs against VEGFA expression might present potential therapeutic agents against tumour growth. In a recent successful application of this approach, systemic administration of miR-26a, which targets cyclins D2 and E2, inhibited hepatocellular carcinoma cell proliferation and tumour progression in mice (Kota et al., 2009). Conventional anti-VEGFA therapies target either circulating protein or cell surface receptors. In contrast, therapies using chemically stabilized miRNAs target VEGFA at the level of intracellular synthesis. This approach, combined with cell-type specific targeting strategies, might permit localized inhibition or fine-tuning of VEGFA expression while minimizing adverse systemic consequences.

Materials and methods

**Cells and lyses**

Human monocytic cells, that is, U937 cells (CRL-1593.2, ATCC), THP1 cells (TIB-202, ATCC), and PBM were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). Human PBM were isolated by leukapheresis, followed by countercurrent centrifugal elutriation (Czerniecki et al., 1997), under a Cleveland Clinic Institutional Review Board-approved protocol that adhered to American Association of Blood Bank guidelines. Human HEK293 cells (CRL-11268, ATCC) were cultured in DME medium supplemented with 4.5 mg/ml glucose and 10% heat-inactivated FBS. Cells were treated with either normoxic (21% O2) or hypoxic (1% O2) conditions in a humidified incubator for 24 h. Cell lysates were prepared in phosphosafe extraction buffer (Novagen) containing protease inhibitor cocktail (Thermo Scientific). Cytoplasmic and nuclear extracts were obtained using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific).

**Plasmid construction, transfection, and dual luciferase activity assay**

pcDNA3-3-Luc-VEGFA HSR (wild type and mutant) and pcDNA3-c-Myc-hnRNP L were generated as described (Ray et al., 2009). U937 cells (2 × 10⁶ cells) were transfected with oligomers including pre-miR miRNA precursors, miRNA-negative control, anti-miR miRNA inhibitors, anti-miR-negative control, and anti-miR mutants (200 nM, Ambion), using GenomONE-Neo EX HVJ Envelope Vector Kit (Cosmo Bio). For anti-miR mutants, nt 3 and 4 of the seed regions of miR-297 (G, U to A, and A) and miR-299 (U, G to A, A) were mutated. The same kit was used to transfect U937 cells (2 × 10⁶ cells) with plasmid DNA (40 µg). For dual luciferase assay, oligomers were cotransfected into U937 cells with FLuc reporter plasmid (40 µg) and the luciferase expressing vector pRL-SV40 (20 µg) to normalize for transfection efficiency, and relative luc activity was measured using dual luciferase assay kit (Promega). For H9K293 cells, 2 × 10⁵ cells were transfected with pre-miR miRNA precursors (100 nM), or cotransfected with FLuc reporter plasmid (2 µg) or pcDNA3-c-Myc-hnRNP L (2 µg) and pRL-SV40 (0.5 µg) as internal transfection control using lipofectamine 2000 (Invitrogen).

**Immunocytochemistry**

U937 cells (about 50% confluence) on glass slides were washed three times with phosphate-buffered saline (PBS) and fixed in 1% paraformaldehyde for 30 min. Fixed cells were washed with PBS and permeabilized with 0.1% Triton X-100 for 15 min. After further washing, the cells were incubated with rabbit polyclonal anti-hnRNP L antibody (Santa Cruz) for 2 h at room temperature. After thorough washing, anti-rabbit Alexa fluor 488 (Invitrogen) was added for 60 min at room temperature. DAPI (Sigma-Aldrich) was added to stain nuclei. The slides were mounted with 90% glycerol in PBS and immunofluorescent images were acquired by confocal microscopy with LaserSharp software.

**Immunoblot analysis**

Cell lysates were subjected to SDS-PAGE (12%). The transferred blot was probed with rabbit anti-human VEGFA polyclonal antibody (Santa Cruz) and HRP-conjugated anti-rabbit secondary antibody (GE Healthcare), and detected with ECL Plus (Amersham). Immunoblot with mouse monoclonal anti-GAPDH-peroxidase (Sigma) antibody provided a loading control. Band intensities were measured using ImageJ software. VEGFA was measured following concentration with rabbit anti-human VEGFA polyclonal antibody (2 µg/ml) and GammaBind Plus Sepharose beads (GE Healthcare) followed by immunoblot with mouse monoclonal anti-VEGFA antibody (Santa Cruz) (Kim et al., 2002). Other antibodies used for immunoblotting were mouse monoclonal anti-c-Myc (Santa Cruz), rabbit polyclonal anti-hnRNP L (Santa Cruz), and mouse monoclonal anti-α-tubulin (Sigma).

**Analysis of RNA by PCR**

Total small RNA was extracted with miRVana miRNA Isolation Kit (Ambion), and quality and quantity determined using a NanoDrop spectrophotometer. miRNA was assessed by real-time PCR using TaqMan probe and primer sets in an ABI PRISM 7000 system (Applied Biosystems), and normalized with hsa-miR-17-5p. Briefly, total small RNA (10 ng) was reversely transcribed using Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems) and amplified using TaqMan 2x Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems). To determine VEGFA and hnRNPL miRNAs, first-strand cDNAs were synthesized with Super Script III reverse transcriptase (Invitrogen) using total RNA (2 µg) extracted with Trizol, and SYBR Green PCR master mix (Applied Biosystems) in an ABI PRISM 7000 system. GAPDH mRNA was used as an internal normalization control. Primers for 120 nt VEGFA PCR product were TATCGCGGA TCAAACTCTAC (forward) and CTCGCCGTGCACTACATTTTCTGT TCCT (reverse); primers for 180 nt hnRNPL product were TTGCCTTATATGGCAATCTGG (forward) and GACTGACGGCAGCAT GATGT (reverse); primers for 96 nt GAPDH product were TGCA CACCAAAGTCTTACGC (forward) and GCGATGAACTGGTCGTA GCG (reverse).

**RNA blot analysis**

RNA blot analysis using locked nucleic acid probes was used to determine miRNAs (Varalilay et al., 2008). Briefly, total RNA (100 µg) was mixed with an equal volume of gel loading buffer II (Ambion), heated at 80 °C for 5 min, snap-cooled, and fractionated by 15% denaturing acrylamide gel electrophoresis. RNA was transferred to Hybond N+ (GE Healthcare) by capillary blotting using 20 × SSC buffers (Invitrogen) and fixed using UV crosslinker. miRCURY LNA detection probes (10 pmol, Exiqon) complementary to the CARE-binding miRNAs were radio labelled with 3 µl T4 polynucleotide kinase (New England Biolabs) and 1 µl [γ-³²P]-ATP (0.4 mMBq) for 1 h at 37 °C. Labelled LNA probes were heated at 95 °C for 1 min, ice-cooled, diluted 1:1000 in pre-warmed (50 °C) PerfectHyb Plus hybridization solution (Sigma) with denatured salmon sperm DNA (20 µg/ml, Ambion), and added to the hybridized UV crosslinked membrane at 50 °C for 1 h. Membranes were washed with 3 × in 0.1% SDS at 50 °C. Decade Marker (Ambion) was used as molecular weight markers. The membranes were stripped with boiled 0.1% SDS, 5 mM EDTA for 30 min, and reprobed with radiolabelled LNA-modified U6 as loading control.
Interaction of hnRNP L with VEGFA mRNA

In vivo interaction of hnRNP L with VEGFA mRNA was determined by immunoprecipitation followed by RT–PCR as described (Shih and Claffey, 1999; Majumder et al., 2009). Briefly, nuclear and cytoplasmic extracts (500 μg) prepared in NE-PER extraction reagent (Thermo) were incubated with Halt Protease Inhibitor Cocktail (EDTA-free, Thermo), RNase inhibitor (Promega), mouse IgG (4 μg), and 50 μl of GammaBind Plus Sepharose beads for 1 h at 4°C. The supernatant was incubated overnight at 4°C with 4 μg of mouse monoclonal antibody against hnRNP L or hnRNP A1 (Santa Cruz), DNA polymerase (Invitrogen) For reverse transcriptase III (Invitrogen) using oligo d(T) and Taq and pre-mRNAs were detected by RT–PCR with Superscript isolated from the same extracts using Trizol reagent. mRNAs and RNA extracted with an equal volume of Trizol reagent NE-PER cytoplasmic or nuclear extraction buffers, resuspended, and RNA extracted with an equal volume of Trizol reagent (Invitrogen) for in vitro cytoplasmic interactions, PCR primers for VEGFA (Shih and Claffey, 1999) generated a 716-nt product resolved by 1.5% agarose gel electrophoresis. A 96-nt PCR product served as a control.

Supplementary data

Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).

Acknowledgements

We are grateful to Abul Arif, Donna Driscoll, and Fulvia Terenzi for helpful suggestions. This work was supported by NIH grants P01 HL029582, R01 GM086430, and P01 HL076491 (to PLF) and by AHA, Great Rivers Affiliate Postdoctoral Fellowships (to PY).

Conflict of interest

The authors declare that they have no conflict of interest.


